GeNeuro Reports Results of Temelimab + Rituximab in P-II (ProTEct-MS) trial for the Treatment of Multiple Sclerosis
Shots:
- The P-II (ProTEct-MS) study evaluates temelimab (54mg/kg) + rituximab in 41 patients with MS whose disability progresses without relapses at Center for Neurology of ASC with ~2400 patients
- The trial met its 1EPs & showed an excellent safety profile & tolerability of higher doses of temelimab with a high-efficacy anti-inflammatory drug, was well tolerated with no treatment-related discontinuations, no serious or sev. TEAEs & no differences in overall clinical or laboratory safety results
- In efficacy results, temelimab as monothx. showed a favorable impact on key MRI parameters measuring neurodegeneration. The observed effect sizes were consistent with previous (CHANGE-MS) & (ANGEL-MS) studies
Ref: Genuero | Image: Genuero
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
